Group a rotaviruses (RVa) are the leading cause of severe diarrhea in young children worldwide. Two live-attenuated RVa vaccines, Rotarix® and RotaTeq® are recommended by World health Organization (WhO) for routine immunization of all infants. Rotarix® and RotaTeq® vaccines have substantially reduced RVa associated mortality but occasionally have been associated with acute gastroenteritis (aGe) cases identified in vaccinees and their contacts. high-throughput assays are needed to monitor the prevalence of vaccine strains in aGe cases and emergence of new vaccine-derived strains following RVa vaccine introduction. In this study, we have developed quantitative real-time RT-PcR (qRT-PcR) assays for detection of Rotarix® and RotaTeq® vaccine components in stool samples. Real-time RT-PcR assays were designed for vaccine specific targets in the genomes of Rotarix® (NsP2, VP4) and RotaTeq® (VP6, VP3-Wc3, VP3-human) and validated on sequence confirmed stool samples containing vaccine strains, wild-type RVa strains, and RVa-negative stools. For quantification, standard curves were generated using dsRNa transcripts derived from RVa gene segments. Rotarix® NsP2 and VP4 qRT-PcR assays exhibited 92-100% sensitivity, 99-100% specificity, 94-105% efficiency, and a limit of detection of 2-3 copies per reaction. RotaTeq® VP6, VP3-Wc3, and VP3-human qRT-PcR assays displayed 100% sensitivity, 94-100% specificity, 91-102% efficiency and limits of detection of 1 copy, 2 copies, and 140 copies, respectively. These assays permit rapid identification of Rotarix® and RotaTeq® vaccine components in stool samples from clinical and surveillance studies and will be helpful in determining the frequency of vaccine strain-associated aGe.
Introduction
Group A rotavirus (RVA) infection is the leading cause of acute gastroenteritis (AGE) in children aged <5 y worldwide and is associated with 453 000 deaths annually, predominantly in developing countries. 1 RVA is transmitted largely through person-to-person contact and improvements in hygiene and sanitation in developed countries do not reduce the prevalence or spread of RVA infection dramatically. 2 RVA vaccines have been identified as the best strategy to decrease the burden associated with severe and fatal rotavirus diarrhea. 3 Live attenuated RVA vaccines administered by the oral route elicit immunity comparable to that induced by natural RVA infections and provides protection against severe diarrhea caused by the major RVA serotypes in circulation. [4] [5] [6] Two live-attenuated oral RVA vaccines, Rotarix ® a monovalent human RVA vaccine (GlaxoSmithKline Inc.) and RotaTeq ® a pentavalent human-bovine (WC3) reassortant vaccine (Merck and Co., Inc.) are recommended by WHO for routine immunization of all infants. 7 Rotarix ® was developed by multiple tissue culture passages of the human G1P [8] parental 89-12 strain. 8 
Rotarix
® was licensed by the US Food and Drug Administration (FDA) in 2008 and is administered in 2 oral doses at 2 and 4 mo of age. 9 RotaTeq ® consists of 5 human-bovine reassortants expressing the 4 most common human RVA G-types, G1, G2, G3, and G4 and the most common human RVA P-type P [8] on a parental bovine-WC3 strain backbone. 10 In RotaTeq ® vaccine, 3 reassortants (WI78-8, BrB-9 and WI79-4) possess a bovine RVA VP3 gene (VP3-WC3) and two reassortants (WI79-9 and SC2-9) contain a human RVA VP3 gene (VP3-human). 11 
RotaTeq
® was licensed by the FDA in 2006 and is administered in 3 oral doses at 2, 4, and 6 mo of age. 9 RVA vaccination has dramatically reduced childhood AGE in developed countries as well as in many developing countries. 7 Rotarix ® and RotaTeq ® are live vaccines that can replicate in vaccinees and are shed in feces following vaccination. Post-vaccination shedding of Rotarix ® and RotaTeq ® vaccine strains in stools is detected in approximately 50% and 10% vaccine recipients respectively. 12, 13 Vaccine virus shedding is more common after the first dose of vaccination in stools collected from 1 to 15 d post-vaccination, indicating viral replication. 13 Immunocompromised patients can show prolonged shedding up to 360 d after the last dose of RotaTeq ® vaccine. 14 Shedding of the vaccine strains from vaccinees can result in transmission of live vaccine virus strains from vaccinated to unvaccinated children. [15] [16] [17] [18] Such shedding could be of substantial benefit in countries with low immunization rates but high mortality caused by RVA. 13 In countries where RVA-associated mortality is low, horizontal transmission of vaccine virus and subsequent vaccine-associated disease could be a potential risk, especially among immunocompromised individuals. 12 Evaluation of the incidence and characteristics of vaccine-virus shedding is important for live, oral vaccines. Horizontal transmission of vaccine virus has been documented for other live, attenuated vaccines, such as varicella-zoster vaccine and oral poliovirus vaccine. 24 Currently, conventional reverse transcription-polymerase chain reaction (RT-PCR) assays, nucleic acid hybridization, and sequencing methods are used to identify and detect vaccine strains in stool samples. 12, [15] [16] [17] 20 RT-PCR based methods are used also for the identification of reassortant strains with mixed constellations of genotype 1 and 2 genes of human group A rotaviruses. 25 RT-PCR of WC3-VP6 gene segment followed by nucleotide sequencing of the PCR amplicons has been used to detect shedding of RotaTeq ® vaccine strains in stool samples post vaccination. 12, 26 Quantitative RT-PCR assays have been developed to determine the in-vitro infectious potency of RotaTeq ® vaccine strains in Vero cells. 27 A dot-blot Northern hybridization assay has been developed to detect RotaTeq ® vaccinederived strains circulating in the community. 20 RT-PCR reverse hybridization strip assays have been developed to distinguish the Rotarix ® G1P [8] vaccine strain from wild type G1P [8] strains. 
Results
Previously only Rotarix ® vaccine strain VP4 and VP7 sequences were available in the GenBank. We performed sequencing of all 11 genes of Rotarix ® vaccine strain. Rotarix ® vaccine strain sequences The complete or nearly complete open reading frames of all 11 genes of the Rotarix ® vaccine (lot number 426332) were determined and deposited into GenBank (see Table 1 for accession numbers). Rotarix ® vaccine strain sequences obtained by in this study were compared with VP4 (JN849113) and VP7 (JN849114) genes of Rotarix ® vaccine strain available in the GenBank. VP4-JX943612 (CDC) sequence showed 99.95% identity to VP4-JN849113 (GenBank), the difference resulting from a degenerate base in the JN849113 sequence. VP4 Rotarix ® vaccine strain sequence determined in this study (GenBank accession number JX943612) shares 99.8% identity with the Rotarix ® VP4 sequence under GenBank accession number JN849151. Rotarix ® VP4 public sequence (JN849151) is from a stool sample of a patient who had received Rotarix ® vaccine. Both the sequences have Rotarix ® specific "C" nucleotide at position 483 bp but public sequence JN849151 lacks Rotarix ® specific "T" nucleotide at position 501. VP7-JX943614 (CDC) sequence displayed 100% identity to the previously deposited VP7-JN849114 (Fig. 1) . The NSP2 assay probe incorporated a modified C-5 propynyl-dC bases and a G-clamp residue to raise the probe Tm ( Table 2) . The Rotarix ® NSP2 qRT-PCR assay detected the Rotarix ® NSP2 gene in all sequence-confirmed Rotarix ® NSP2 positive samples (n = 24) tested (Table 3A and Fig. 2 ) and detected one sample which, by sequence analyses, appeared to be a mixed infection of wild-type G1P [8] and Rotarix ® . The Rotarix ® NSP2 assay showed no detection of other wild-type G1P [8] samples (n = 200), other RVA genotype samples (n = 60) or with RVA negative samples (n = 50) ( Table 3A and Fig. 2 ). When tested using laboratory reference strains (Table 4) , the Rotarix ® NSP2 assay showed no amplification with human or animal strains of non-G1P [8] genotypes. Thus, the Rotarix ® NSP2 qRT-PCR assay exhibited 100% sensitivity and 99% specificity with a PPV of 96% and NPV of 99% ( Table 5) . Using a 10-fold dilution series of Rotarix ® NSP2 vaccine derived dsRNA transcript, the efficiency of Rotarix ® NSP2 assay was calculated to be 94% with a limit of detection of 2 copies (Table 5 and Fig. 2) .
Rotarix ® VP4 assay To obtain a secondary screening assay for detection of Rotarix ® in stool samples, the Rotarix ® VP4 gene was targeted. The Rotarix ® VP4 (JX943612) sequence has 99% identity to wild-type G1P [8] strain Wa (FJ423116) but has two nucleotide mismatches, one at position 483 bp ("C" in Rotarix, "T" in wild-type G1P [8] strains) and other at position 501 bp ("T" in Rotarix, "G" in wild-type G1P [8] strains (Fig. 1) . The Rotarix ® VP4 qRT-PCR probe was designed to incorporate these nucleotide mismatches and incorporated 2 G-clamp residues to raise the probe Tm ( Table 2) . Rotarix ® VP4 qRT-PCR assay detected the Rotarix ® VP4 gene in 23 out of 25 sequence-confirmed Rotarix ® VP4 positive samples tested (Table 3B) . Two sequence confirmed Rotarix ® VP4 positive samples were not detected by the Rotarix ® VP4 real-time assay. The limit of detection of the Rotarix ® VP4 conventional RT-PCR assay used for generating amplicons and sequences for the Rotarix ® VP4 gene is 228 copies (data not shown). The Rotarix ® VP4 assay yielded negative results for wild-type G1P [8] samples (n = 278), samples of different RVA genotypes (n = 60) or RVA negative samples (n = 50) ( Table 3B ). When tested with laboratory reference strains (Table 4) , the Rotarix ® VP4 assay did not detect human or animal strains of non-G1P [8] genotypes. Thus, the Rotarix ® VP4 qRT-PCR assay exhibited 92% sensitivity and 100% specificity with a PPV of 100% and NPV of 99% ( Table 5) . Using a 10-fold dilution series of Rotarix ® VP4 vaccine derived dsRNA transcript), the efficiency of Rotarix ® VP4 assay was calculated to be 105% with a limit of detection of 3 copies ( Table 5) . RotaTeq ® qRT-PCR assays RotaTeq ® VP6 assay The RotaTeq ® VP6 gene was selected to design a primary screening assay to detect the presence of bovine-WC3 backbone in all five RotaTeq ® component strains. The primers and probe were designed to detect the VP6 genes of RotaTeq ® and the WC3 parental backbone strain (Fig. 1) . The RotaTeq ® VP6 probe contained 2 modified C-5 propynyl-dC bases ( Table 2) . RotaTeq ® VP6 qRT-PCR assay detected the RotaTeq ® VP6 gene in all sequence confirmed RotaTeq ® VP6 positive samples (n = 74) tested (Table 6A and Fig. 3 ) and yielded negative results for wild-type RVA positive samples (n = 353) and RVA negative stools samples (n = 50) ( Table 6A and Fig. 3 ). When tested using laboratory reference strains (Table 4) , the RotaTeq ® VP6 assay detected RotaTeq ® vaccine and animal strains (B223, WC3, NCDV, RRV) and human-animal reassortant strains (RO1845 and CC425) but no amplification was observed with human RVA reference strains. Thus, the RotaTeq ® VP6 qRT-PCR assay exhibited 100% sensitivity and 98.6% specificity with a PPV of 92.5% and NPV of 100% ( Table 5) . Using a 10-fold dilution series of RotaTeq ® VP6 vaccine derived dsRNA transcript, the efficiency of RotaTeq ® VP6 assay was calculated to be 91% with a limit of detection of 1 copy ( Table 5 and Fig. 3) . RotaTeq ® VP3 (WC3 and human) assays The VP3 gene was selected to design secondary assays to detect the VP3-WC3 gene present in 3 RotaTeq ® component strains and VP3-human gene found in 2 component strains. Primers and probe were designed flanking the nucleotides specific to RotaTeq ® VP3-WC3 and RotaTeq ® VP3-human genes (Fig. 1) . Primer and probe sequences are shown in Table 2 .
Validation of RotaTeq ® VP3-WC3 and VP3-human realtime assays were performed on sequence confirmed RotaTeq (Table 6B) . When tested on laboratory reference strains (Table 4) , the RotaTeq ® VP3-WC3 assay amplified RotaTeq ® vaccine and bovine RVA strains (B223, WC3, NCDV) and human-bovine reassortant strain CC425, but no amplification was observed with human RVA reference strains. Thus, the RotaTeq ® VP3-WC3 qRT-PCR assay exhibited 100% sensitivity and 94.5% specificity with a PPV of 90% and NPV of 100% ( Table 5) . Using a 10-fold dilution series of WC3 VP3 derived dsRNA transcript, the efficiency of RotaTeq ® VP3-WC3 assay was calculated to be 101% with a limit of detection of 2 copies ( Table 5) .
The RotaTeq (Table 6C) . The RotaTeq ® VP3-human assay also detected RotaTeq ® VP6 negative human wild-type G1P [8] , G3P [8] , G4P [8] , and G9P [8] strains when tested on a panel of RVA strains of different genotypes (n = 60; data not shown) but didn't exhibit amplification when RVA negative samples (n = 41) were tested (Table 6C) . When tested on laboratory reference strains ( (Table 5) . Using a 10-fold dilution series of Wa-VP3 derived dsRNA transcript, the efficiency of RotaTeq ® VP3-human assay was calculated to be 102% and the limit of detection was 140 copies ( Table 5) . Four samples found to be positive by RotaTeq ® VP6 qRT-PCR assays were negative by both the RotaTeq ® VP3-WC3 and RotaTeq ® VP3-human qRT-PCR assays.
Discussion
In this study, we have developed one-step qRT-PCR assays for detecting Rotarix ® and RotaTeq ® vaccine strain components in stool samples. Designing an assay specific for Rotarix ® vaccine strain was a challenge as Rotarix ® vaccine was derived from a wild-type G1P [8] strain. Based on the sequence differences between the Rotarix ® vaccine strain sequence and wild-type strain sequences, the Rotarix ® NSP2 gene was identified as the best target for designing a primary screening qRT-PCR assay for detecting Rotarix ® vaccine strain in stool samples. The Rotarix ® NSP2 qRT-PCR assay was able to detect the Rotarix ® NSP2 gene in a sample with mixed infection of wild-type G1P [8] strain and Rotarix ® vaccine strain which was confirmed by the presence of degenerate bases in sequencing chromatograms. However, the Rotarix ® VP4 qRT-PCR assay could not detect Rotarix ® VP4 gene in that sample, probably due to the poorer limit of detection of the Rotarix ® VP4 real-time assay or reduced sensitivity of the Rotarix ® VP4 probe for the Rotarix ® VP4 gene in the presence of a wild-type P [8] gene in a mixed infection. One sequence confirmed Rotarix ® VP4 positive sample was missed by the Rotarix ® VP4 qRT-PCR assay, probably due to poor sample quality or degradation of the VP4 gene segment as obtaining an amplicon for conventional RT-PCR and sequencing was difficult for this sample. When the sample was analyzed by silver-stained PAGE 30 no RVA genomic RNAs were visible, thus suggesting that the quality and/or quantity of intact genomic RNA in this sample were low.
The RotaTeq ® VP6 assay proved to be a robust, efficient screening assay to identify the bovine-WC3 parental strain present in all five RotaTeq ® reassortants. RotaTeq ® VP3 secondary screening assays (VP3-WC3 and VP3-human) were able to detect RotaTeq ® VP3-WC3 and RotaTeq ® VP3-human genes NSP2 qRT-PCR assay should then be tested by the Rotarix ® VP4 qRT-PCR secondary screening assay. The samples testing positive by the RotaTeq ® VP6 assay should then be tested by using the RotaTeq ® VP3-WC3 and RotaTeq ® VP3-human secondary screening assays. For laboratories with high-throughput real-time PCR capacity, these screening assays could be run concurrently. We also recommend that all the RVA positive samples be genotyped using conventional RT-PCR methods [33] [34] [35] [36] or sequencing. In addition, we recommend that all samples found to contain vaccine strain genes by the screening qRT-PCR assays should be confirmed by sequencing.
The limitations of this study are that the qRT-PCR assays were designed to detect only a limited number of genes in each vaccine, for Rotarix ® (NSP2 and VP4) and for RotaTeq ® (VP6 and VP3). Thus, these assays won't detect reassortants produced by exchange of other segments between wild-type RVA and vaccine strains as detected previously. 24 In addition, the RotaTeq ® VP6 and RotaTeq ® VP3-WC3 assays may detect wild-type bovine strains in human samples containing human-animal reassortants. The RotaTeq ® VP3-human assay can detect Wa-like human strains thus this assay should be used only as a secondary assay to screen RotaTeq ® VP6 positive samples.
Conclusion
The assays reported in this study can be used for rapid detection of Rotarix ® and RotaTeq ® vaccine strains and potential vaccine-derived reassortant strains. These assays will be useful for high-throughput screening of stool samples during the course of monitoring the effectiveness and safety of RotaTeq ® and Rotarix ® vaccines and for monitoring the potential transmission of vaccine strains and strain components within communities.
Materials and Methods

Sequencing of Rotarix ® vaccine strain and vaccine strain sequences
To design qRT-PCR assays for RVA vaccine strains, we performed full genome sequencing of Rotarix ® vaccine stock as only VP4 and VP7 sequences for Rotarix ® had been deposited in GenBank (accession numbers JN849113 [VP4] and JN849114 [VP7]). RNA from Rotarix ® vaccine (GlaxoSmithKline, lot number 426332) was extracted using the QIAGEN QIAamp Viral RNA mini kit (QIAGEN, cat. number 52904). Extracted dsRNA was denatured for 5 min at 95 °C and all the 11 genes of Rotarix ® vaccine strain were amplified with consensus primers for each genome segment 33,34,37-39 using the QIAGEN One-Step RT-PCR kit (QIAGEN, cat. number 210210). DNA from PCR amplified products was extracted using the QIAGEN gel extraction kit (QIAGEN, cat. number 28706) and added to a cycle sequencing reaction performed with the BigDye Terminator v3.1 Cycle sequencing kit (Life Technologies, cat. number PN 4337455). Products from cycle sequencing reaction were purified using BioMag ® Carboxyl beads 40 and analyzed on an ABI Prism 3130xl Genetic Analyzer using 3130 POP-7 TM (Life Technologies, cat. number 4352759). Sequences were edited and analyzed using Sequencher 5.0 (Gene Codes Corp., Inc.). The sequences of all the 11 genes of Rotarix ® vaccine strain were deposited into GenBank. RotaTeq ® vaccine strain sequences for bovine-WC3 and human genes were retrieved from GenBank (RotaTeq ® VP6-GU565067, GU565056, GU565078, GU565045; RotaTeq ® VP3-WC3-GU565043, GU565076, GU565087; RotaTeq ® VP3-human GU565065 and GU565054). Rotarix ® and RotaTeq ® vaccine strain gene sequences were aligned to their respective wild type (human or bovine-WC3) gene sequences available in GenBank to generate multiple alignments using GeneDoc and Multalign. 41 
Primer and probe design
The consensus sequences obtained from multiple alignments of Rotarix ® (NSP2 and VP4) and RotaTeq ® (VP6, VP3-WC3, and VP3-human) genes were used to design TaqMan assays for each gene which targeted gene regions or nucleotide substitutions specific to vaccine strains. Multiple probe and primer sets were designed manually and degenerate bases were introduced into the primer or probe sequences to account for sequence variation observed in sequence alignments of above-mentioned genes. The primer and probe sequences were checked for specificity using NCBI-Nucleotide blast [nblast] (http://blast.ncbi.nlm.nih.gov/ Blast.cgi) and were checked for self-annealing sites, hairpin loop formation and 3′ complementarity using the IDT oligonucleotide calculator (http://www.idtdna.com/analyzer/Applications/ OligoAnalyzer/). The melting temperatures (T m) of primers and probes were increased to 58-60 °C and 68-70 °C, respectively, using C-5 propynyl-dC (pDC) or AP-dC (G-clamp) substitutions as necessary (Glen Research, cat. numbers 10-1041-90 and 10-1097-90). All probes were labeled with a 5′-carboxyfluorescein (FAM) (Glen Research, cat. number-10-5901-95) at RNA extraction of clinical specimens and reference strains Vaccine-strain positive stool samples containing Rotarix ® (n = 25), RotaTeq ® (n = 74), and wild-type RVA (n = 353) strains or RVA-negative (n = 50) stool samples were obtained from routine domestic and international RVA surveillance conducted by CDC. RVA laboratory cultured strains (n = 25) representing various VP7 (G) and VP4 (P) genotypes also were used to screen, optimize, and validate the vaccine strain detection assays. RNA from clinical samples and 25 reference strains ( Table 4) was extracted using the automated KingFisher extraction system (Thermo Scientific), MagNA Pure compact or MagNA Pure 96 (Roche Applied Science) instruments according to manufacturer's instructions. All extracted RNAs were stored at -80 °C until analyzed.
Conventional RT-PCR and sequencing
To confirm the samples as vaccine strain positive or negative, RT-PCR of VP4, 33-36 VP6, 42 NSP2, 37, 42 VP3-WC3 (Forward primer-5′-AACCAAAGAT GACTACGAGA A-3′ and Reverse primer-5′-CTGTGATCTG ATACTAGCG-3′) and VP3-human (Forward primer-5′-TCATATCACG TTTGGACAA TCACGAAT-3′ and Reverse primer-5′-AATTGATTCC GAGTTTTGTA CTCTCT-3′) genes were performed and the resulting amplicons were sequenced by using an ABI 3130 xl sequencer. The consensus sequence of each gene was compared with available RVA sequences in GenBank and to Rotarix ® and RotaTeq ® vaccine strain sequences for strain identification.
Real-time RT-PCR
All qRT-PCR assays were performed in 96-well ABI Fast plates using the GeneAmp EZ rTth RNA PCR kit (Applied Biosystems, Inc.). Single well denaturation, reverse transcription, and amplification were performed on a 7500 Fast Real-Time PCR System in fast mode (Applied Biosystems, Inc.). The reaction mixture (25 µL/well) consisted of 5 µL of 5X EZ buffer, 1.2 µM dNTPs, 2.5 mM Mn(OC) 2 , 2.5 U/µL rTth polymerase, 100 nM probe, 200 nM each primer (RotaTeq ® VP6 assay); 100 nM probe, 400 nM each primer (RotaTeq ® VP3-WC3 assay); 200 nM probe, 400 nM each primer (RotaTeq ® VP3-H, Rotarix ® NSP2, and Rotarix ® VP4 assays) and nuclease free water to 23 µL. Two microliters of extracted RNA were added to each sample well and 2 µL of nuclease free water was added in the no template control (NTC) wells. All the samples and negative controls were tested in duplicate. The cycling conditions consisted of denaturation of dsRNA for 5 min at 95 °C, reverse transcription for 30 min at 50 °C, 1 min at 95 °C and 45 amplification cycles consisting of 15 s at 95 °C and for 1 min at 60 °C.
Screening, optimization, and validation of vaccine strain detection assays
Multiple probe and primer sets designed for Rotarix ® (NSP2, VP4) were screened using Rotarix ® vaccine as positive control and wild-type samples including G1P [8] , G2P [4] , G3P [8] , G4P [8] , and other genotypes in circulation. All the probe and primer sets designed for RotaTeq ® (VP6, VP3-WC3, VP3-human) genes were screened using wild type (G1, G2, G3, G4, and P8) RVA samples and RotaTeq ® vaccine as positive control. For each real-time assay, the probe and primer set with the best sensitivity, specificity, efficiency, and limit of detection on vaccine-derived dsRNA transcripts were selected for optimization. For assays having more than one specific probe:primer pair, the probe and primer set showing a sigmoidal amplification curve with the lowest cycle threshold (C t ) value was selected for optimization. Selected probe and primer sets were optimized by performing each assay at three different probe:primer concentrations (100:200 nM, 100:400 nM, and 200:400 nM). The probe:primer concentration for each assay showing amplification of its respective template at the lowest C t value with low background amplification was selected for subsequent experiments. The optimized vaccine strain detection assays were then validated using the clinical samples and 25 reference strains ( Table 4) . Double stranded RNA (dsRNA) positive control transcripts Primers with T7 promoter sequences at the 5′ end of both the forward and reverse primers were designed to generate fulllength amplicons for Rotarix ® (NSP2, VP4) and RotaTeq ® (VP6, VP3-WC3, VP3-human) genes ( Table 7 , cat. number AM1626) was used to generate dsRNA transcript according to manufacturer's instructions. Concentrations of the transcripts were measured at 260 nm using a NanoDrop ND-1000 spectrophotometer (Thermo Scientific). The efficiency and limit of detection of the Rotarix ® and RotaTeq ® vaccine-specific qRT-PCR assays were determined by analyzing Rotarix ® (NSP2, VP4) and RotaTeq ® (VP6, VP3-WC3, VP3-human) qRT-PCR assays using 10-fold dilution series of their respective transcripts. 10-fold dilution series of all the transcripts (10 -3 to 10 -12 ) were prepared in DEPC-treated water containing 100 ng/µL yeast carrier RNA (Ambion, cat. number AM7118). A standard curve was generated by plotting the log of copy number against C t value and efficiency of each assay was calculated from the slope of the standard curve. Copy number of each assay was calculated by using the formula:
Copy number (molecules/µL) = [concentration (ng/µL) × 6.022x10 23 (molecules/mol)]/ [length of amplicon × 650 (g/mol) × 10 9 (ng/g)].
Assay performance calculations
The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of each qRT-PCR assay were calculated using standard procedures.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
